囊状支气管扩张术后咯血复发预测列线图表1

用于预测囊状支气管扩张患者介入术后咯血复发的列线模型数据表,包含预测因子和模型评估结果。

NIAID Data Ecosystem
浏览 8
表格cystic bronchiectasisnomogramhemoptysisbronchial artery embolizationrecurrence prediction
Table 1_Development and validation of a nomogram for predicting hemoptysis recurrence in cystic bronchiectasis patients following bronchial artery embolization.docx

基本信息

模态
表格
大小
0.000290595 GB
许可
CC BY 4.0
创建/更新时间
2026-10-08
版本
v1

资源简介

囊状支气管扩张术后咯血复发预测列线图表1

【一句话概览】

本数据集是 figshare 公开的结构化表格数据集,收录 1 个文件、合计 290.60 KB,主题涵盖 cystic bronchiectasis、nomogram、hemoptysis、bronchial artery embolization、recurrence prediction,可用于统计建模、特征工程与队列分析,CC BY 4.0 许可开放获取。

【数据集背景】

本数据集源站标题为《Table 1_Development and validation of a nomogram for predicting hemoptysis recurrence in cystic bronchiectasis patients following bronchial artery embolization.docx》。配套论文《Embosphere microspheres size for bronchial artery embolization in patients with hemoptysis caused by bronchiectasis: a retrospective comparative analysis of 500–750 versus 700–900 μm microspheres》发表于 BMC Pulmonary Medicine(2024),DOI:10.1186/s12890-024-03019-4。源站首次发布:2025-05-15。

【数据内容】

源站原始描述:BackgroundHemoptysis is a life-threatening manifestation frequently observed in patients with cystic bronchiectasis (CB), a radiologically defined subtype of bronchiectasis. Bronchial artery embolization (BAE) is widely employed as an effective interventional therapy for controlling hemoptysis. Despite its clinical utility, the risk of recurrence remains high, particularly in patients with CB. Currently, no reliable predictive model specifically targeting CB-related hemoptysis recurrence followi…

【数据结构与技术规格】

文件数 1 个,合计 290.60 KB。Table 1_Development and validation of a nomogram for predicting hemoptysis recurrence in cystic bronchiectasis patients following bronchial artery emb.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document,290.60 KB。数据集 DOI:10.3389/fmed.2025.1582008.s001。

【主题与分类】

源站学科分类:Foetal Development and Medicine。主题标签:cystic bronchiectasis、nomogram、hemoptysis、bronchial artery embolization、recurrence prediction。

【适用方向】

结构化表格数据可直接用于统计建模、特征工程与队列分析。

【获取与许可】

源站页面:https://frontiersin.figshare.com/articles/dataset/Table_1_Development_and_validation_of_a_nomogram_for_predicting_hemoptysis_recurrence_in_cystic_bronchiectasis_patients_following_bronchial_artery_embolization_docx/29068376

使用许可:CC BY 4.0(https://creativecommons.org/licenses/by/4.0/)。

规范引用:Duan, Yuxin; Sui, Weifan; Cai, Zefeng; Xia, Yimao; Li, Jianyun; Fu, Jianhua (2025). Table 1_Development and validation of a nomogram for predicting hemoptysis recurrence in cystic bronchiectasis patients following bronchial artery embolization.docx. Frontiers. Dataset

官方服务

专家保障全链路合规授权与标注交付

陕川双基地 × 超十家三甲医院直连

从合规授权、采集治理、专业标注到数据集交付,我们提供全链路闭环服务,让高质量临床数据即拿即用。

⚡️ 需要原始数据或标注支持?联系我们获取定制方案。

帮我联系

下载信息

注册下载

需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。

暂未开放

公开下载

无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。

免登录

有偿下载

公开数据集受托下载与技术交付服务。

提供高速下载与技术交付服务(收技术服务费,非数据销售)

暂未开放

当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。

使用方式

数据集获取(Figshare)

命令行下载

curl -L -o "Table 1_Development and validation of a nomogram for predicting hemoptysis recurrence in cystic bronchiectasis patients following bronchial artery emb.docx" "https://ndownloader.figshare.com/files/54549545"

文件清单

  • Table 1_Development and validation of a nomogram for predicting hemoptysis recurrence in cystic bronchiectasis patients following bronchial artery emb.docx(290.60 KB)

文件总体积 290.60 KB(源站 API 实测)。

数据加载示例(图像类)

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

BackgroundHemoptysis is a life-threatening manifestation frequently observed in patients with cystic bronchiectasis (CB), a radiologically defined subtype of bronchiectasis. Bronchial artery embolization (BAE) is widely employed as an effective interventional therapy for controlling hemoptysis. Despite its clinical utility, the risk of recurrence remains high, particularly in patients with CB. Currently, no reliable predictive model specifically targeting CB-related hemoptysis recurrence following BAE has been established, highlighting the need for a tailored prognostic tool in this population.
ObjectiveThis study aimed to develop and validate a model to predict the recurrence of hemoptysis in CB patients following BAE, enabling individualized clinical management and prevention strategies.
MethodsA retrospective study was conducted on 111 CB patients who underwent BAE between January 2015 and June 2020. Clinical, radiological, and laboratory data were collected for analysis. Least absolute shrinkage and selection operator (LASSO) regression was applied to identify relevant predictive variables, followed by multivariable Cox proportional hazards regression to determine independent prognostic factors. Based on these predictors, a nomogram was constructed. Its performance was assessed using the concordance index (C-index), receiver operating characteristic (ROC) curves, area under the curve (AUC), calibration plots, and decision curve analysis (DCA).
ResultsFive independent predictors were identified: history of hemoptysis (HR = 3.42, 95% CI: 1.64–7.12, p = 0.001), diabetes (HR = 15.0, 95% CI: 4.69–48.1, p The nomogram is a reliable tool for predicting hemoptysis recurrence in CB patients after BAE. It facilitates early identification of high-risk patients, enabling timely, targeted interventions and improved outcomes.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fmed.2025.1582008.s001(source: https://frontiersin.figshare.com/articles/dataset/Table_1_Development_and_validation_of_a_nomogram_for_predicting_hemoptysis_recurrence_in_cystic_bronchiectasis_patients_following_bronchial_artery_embolization_docx/29068376)。

数据缺失?

依托陕西、四川两大基地,我们与超过十家三甲医院建立直接合作关系,覆盖合规授权、采集治理、专业标注、数据交付的全流程,为AI医疗团队提供即拿即用的高质量临床数据。

⚡️ 需要数据支持或标注服务?立即联系我们获取专业方案。

获取专属数据定制方案